Ray Therapeutics is a company focused on developing innovative optogenetic gene therapies aimed at treating patients with blinding diseases. By creating technology that enhances the understanding of rare retinal conditions, the company strives to empower healthcare professionals to effectively diagnose, cure, and manage inherited retinal diseases. Through its commitment to advancing optogenetics, Ray Therapeutics seeks to improve the quality of life for those affected by these debilitating conditions.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Kate Farms, Inc. specializes in the production of plant-based meal replacement shakes and tube feeding solutions, catering to individuals with various dietary and medical needs. Established in 2011 and headquartered in Santa Barbara, California, with an additional office in Waltham, Massachusetts, the company has become a leader in vegan nutrition. Its enteral formulas are designed for easy digestion and are free from common allergens such as dairy, soy, and gluten, making them suitable for a wide range of patients. Clinicians have reported positive outcomes, including reduced gastrointestinal intolerance and improved nutritional status for users. By combining advanced scientific research with natural ingredients, Kate Farms aims to enhance health and well-being, empowering caregivers, healthcare professionals, and patients to choose effective nutritional solutions. The company's commitment to quality ensures that everyone has access to nourishing options that promote overall health.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
TheraXyte BioScience is a biotechnology company specializing in extracellular vesicle (EV)-mediated drug delivery and the development of novel therapeutics based on EVs. The company has created an advanced drug delivery platform, known as TAXY, which facilitates the mass production of customizable EVs at a Good Manufacturing Practice (GMP) level. This platform is designed to efficiently package therapeutic payloads and target specific organs or cells, enabling the effective release of drug molecules and biological agents. TheraXyte's mission is to bridge the gap between laboratory research and clinical applications, addressing significant challenges in therapeutic delivery and making a meaningful impact on human health through innovative EV-based solutions.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Engimmune Therapeutics is a biotechnology company focused on developing innovative T cell receptor (TCR) therapies for cancer treatment, particularly targeting solid tumors. The company utilizes advanced technologies, including genome editing, high-throughput screening, deep sequencing, and machine learning, to create highly potent and specific immunotherapies. By addressing critical challenges in efficacy and safety, Engimmune aims to provide effective solutions for patients facing serious diseases with significant unmet medical needs. Through its comprehensive platform, the company is dedicated to advancing the next generation of TCR-based therapies, contributing to the evolving landscape of cancer treatment.
Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
Creating novel bispecific antibodies that activate the immune system to fight cancer
BioMason is a biotechnology start-up focused on the building and construction industry, founded in 2012 and headquartered in Research Triangle Park, North Carolina. The company specializes in the production of biological cement-based masonry materials using natural microorganisms and chemical processes. Its product offerings include concrete masonry tiles suitable for various applications, biocement for dust control, and solutions for soil stabilization. BioMason aims to innovate the construction sector by providing sustainable alternatives that reduce environmental impact and enhance the efficiency of building practices.
Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.
Developer of an innovative biological platform designed to focus on scaling up the manufacture of proteins and peptides. The company's platform develops the right large-scale production of molecules by testing them through various expressions such as fungi, yeast, or bacteria, enabling clients to get sustainable solutions for food, agriculture, and energy at attractive costs and quantities.
Operator of a pioneering private biotech company intended for vivo direct cell reprogramming for cancer immunotherapy. The company's proprietary reprogramming technologies develop gene therapy products that ignite efficient and personalized immune responses to establish a robust pipeline of off-the-shelf cancer immunotherapies, activating personalized anti-cancer immune defenses for the benefit of patients in need by offering new treatment avenues for cancers resistant to conventional methods, enabling patients to acquire new forms of treatment for cancer resistant to conventional treatment methods.
We leverage our patent-pending technology to produce nutritionally equivalent breastmilk from cultured human mammary cells. With Biomilq, families can achieve the recommended six months of exclusive breastfeeding while alleviating the climate impacts of bovine-based infant formula.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Doctor Anywhere Pte Ltd is a Singapore-based telehealth company that provides an online platform for health and wellness solutions. Established in 2016, the company specializes in video consultations, allowing patients to consult with licensed and registered doctors for various medical needs. Its digital platform offers on-demand healthcare services that are designed to be simple, seamless, and convenient, catering to the evolving lifestyle preferences of users. By integrating a range of health services, Doctor Anywhere enables patients to receive appropriate diagnoses, medication, and e-prescriptions, facilitating access to healthcare anytime and anywhere. The company aims to improve health outcomes through technology, addressing modern healthcare challenges and enhancing the overall patient experience.
Genomatica, Inc. specializes in developing innovative manufacturing processes that convert renewable feedstocks into intermediate and basic chemicals. Utilizing its proprietary biotechnology platform, the company engineers microorganisms to facilitate fermentation-based production, focusing on a pipeline of 20 key chemicals, including butanediol and butadiene. Genomatica has established itself as a leader in bioengineering, aiming to foster a transition to sustainable materials. Its technology has gained recognition for commercializing processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is important in cosmetics and personal care products. The company is also advancing research in bio-nylon. Genomatica's achievements have been acknowledged through several awards, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol. Founded in 1998 and headquartered in San Diego, California, Genomatica focuses on enhancing the economics, sustainability, and performance of chemical production.
Aristea Therapeutics is a clinical-stage drug development company based in San Diego, California, founded in 2018. The company focuses on creating novel therapies for serious inflammatory diseases and autoimmune conditions. Its research and development efforts are concentrated on addressing unmet medical needs for patients suffering from various conditions, including palmoplantar pustulosis, hidradenitis suppurativa, inflammatory bowel disease, familial Mediterranean fever, and Behçet's disease. By employing a focused and agile approach, Aristea aims to provide innovative treatment options that improve patient outcomes in these challenging therapeutic areas.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
Availity, L.L.C. is a Jacksonville, Florida-based company that specializes in internet-based health information exchange services. Founded in 2001, Availity enhances the communication flow among healthcare providers, health plans, and other stakeholders. Its offerings include various solutions such as CareRead, which facilitates patient information entry via magnetic stripe-enabled member ID cards, and CareProfile, which provides access to electronic health records. The company also offers patient communication tools for online interactions and appointment requests, as well as CarePrescribe, an electronic prescribing system that ensures up-to-date medication information and drug interaction checks. Additionally, Availity’s CareCost Estimator determines patient financial responsibilities in real-time, while CareCollect streamlines the collection of patient payments through card swipes. Availity serves a diverse clientele, including physician offices, hospitals, integrated delivery networks, pharmacies, laboratories, and imaging centers.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
The BBI Group has been a trusted partner to some of the world’s leading diagnostic and healthcare organisations for over 25 years. Founded upon the success of the superior quality and performance of our gold reagents, our organisation has grown to incorporate 3 businesses delivering excellence in diagnostic assay development and manufacturing across a range of sectors, and the supply of consumer healthcare products.
Chromologics ApS is a Danish biotechnology company based in Søborg, founded in 2017 as a spin-out from the Technical University of Denmark. The company specializes in the development of bio-based solutions for natural food colorants, with a focus on innovative products that can replace existing natural colorants like carmine and betanin. Chromologics has created a fungal biotechnology platform to produce its flagship product, ChromoRed, which represents a new generation of natural red food colorants. Through its advancements, Chromologics aims to provide sustainable alternatives in the food industry.
Esco Lifesciences Group specializes in providing technology-based products and services aimed at the life sciences and healthcare sectors. The company supports various aspects of academic research, scientific discoveries, clinical practice, and biopharmaceutical research and development. Its offerings are designed to facilitate the invention, discovery, and commercialization processes in the industry, ultimately enabling customers to lead healthier and safer lives through advanced technological solutions.
Noom, Inc. is a mobile health coaching company that focuses on preventing and managing chronic conditions such as obesity, diabetes, and hypertension. Founded in 2008 and headquartered in New York, with additional offices in Seoul and Tokyo, Noom combines technology with human empathy to facilitate behavior change. Its platform includes evidence-based curricula, trained cognitive behavior coaches, and mobile tracking tools, allowing users to engage in personalized health management. Noom's direct-to-consumer applications have successfully reached over 47 million users globally, and the company has expanded its offerings to include programs for pre-hypertension and diabetes management, as well as its original weight loss initiatives. By leveraging the recognition from the CDC's Diabetes Prevention Program, Noom aims to provide scalable solutions for individuals seeking to improve their health outcomes.
Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.
Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.
AMSilk GmbH, based in Munich, Germany, specializes in producing spider silk proteins and biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film used for protective coatings in medical devices, as well as biosteel spider silk fibers. AMSilk also develops over-the-counter wound care products like SanaSilk, designed to protect the skin, and provides spider silk-based solutions for surgical applications. Additionally, the company produces spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Its offerings include both raw materials and semi-finished products such as membranes and films. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company was founded in 2008.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, facilitating real-time online consultations. The platform also allows patients to order laboratory tests that can be conducted at home and helps them locate nearby hospitals and clinics. Additionally, HaloDoc provides access to licensed medical laboratory services and a medical delivery service known as ApotikAntar, further enhancing the convenience and accessibility of healthcare for its users.
Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.
Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, United Kingdom, with additional offices in the Netherlands, specializes in carbon recycling services. The company has developed scalable technology that converts carbon dioxide from industrial waste gas into clean, nutritious, and sustainable single-cell protein. This innovative process not only helps to reduce the carbon footprint of polluting industries but also offers sustainable alternatives to traditional feed sources such as soy and fishmeal. By transforming emissions into valuable protein, Deep Branch Biotechnology aims to contribute to a more sustainable future in the feed industry.
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.
BioPhero ApS provides bio-based pheromones for pest management. The company was founded in 2016 and is based in Kongens Lyngby, Denmark.
Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
ZELP Ltd. is a London-based company established in 2017 that specializes in manufacturing a wearable device designed to reduce ethane emissions in livestock. The company's innovative technology aims to mitigate the environmental impact associated with the livestock industry, addressing concerns related to greenhouse gas emissions and sustainability. By focusing on this niche sector, ZELP is contributing to efforts aimed at promoting more environmentally friendly practices within agriculture.
Altasciences Clinical Research, encompassing Algorithme Pharma, Vince & Associates Clinical Research and Algorithme Pharma USA, is one of the early phase clinical research organizations (CROs) in North America. As a full-service CRO, we have extensive expertise in the execution of a wide range of Phase I/II clinical studies, especially complex trials in healthy normal volunteers and patient populations.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Vestaron Corporation is a biotechnology company that specializes in developing, manufacturing, and selling peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T for thrips in vegetables and ornamentals, Spear-Lep for various fruits and vegetables, and Leprotec for field use. The company's products are designed to enhance the safety, efficacy, and sustainability of agricultural practices while being safe for humans, birds, fish, and pollinators. By utilizing peptides derived from spiders, Vestaron aims to provide innovative solutions for agriculture, animal health, and commercial pest control applications.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
MycoWorks LLC specializes in the research, design, and manufacturing of sustainable leather alternatives derived from natural mycelium. Established in 2013 and based in San Francisco, the company produces a proprietary material called Reishi, which is water-resistant and customizable in texture and features. Reishi is designed to mimic the performance and feel of traditional leather while being animal-free and environmentally friendly. MycoWorks employs a unique platform known as Fine Mycelium to create this innovative biomaterial, which boasts qualities such as strength, durability, and biodegradability. The company aims to provide natural alternatives to conventional materials like plastic foams, textiles, and leather, catering to industries such as aerospace, automotive, apparel, and architectural interiors. Through its carbon-negative production process, MycoWorks offers a rapidly grown solution that aligns with sustainable design principles.
Stargazer Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2018. The company specializes in developing and manufacturing therapies for rare eye diseases, with a particular focus on Stargardt’s disease, a form of juvenile retinal degeneration. Currently operating in stealth mode, Stargazer Pharmaceuticals aims to provide novel treatment options for conditions that lack existing therapies, thus enabling healthcare professionals to better address the needs of patients with these rare diseases.
The Protein Brewery B.V., founded in 2019 and based in Breda, the Netherlands, specializes in developing and manufacturing animal-free protein products through innovative fermentation technologies. As a spin-out from BioscienZ, the company focuses on producing Fermotein, a fungi-based protein designed to replace traditional animal proteins. This sustainable production method utilizes significantly less land and water compared to conventional agriculture, while delivering proteins that maintain essential amino acids, vitamins, and minerals necessary for a balanced diet. The Protein Brewery aims to provide consumers with high-quality protein-integrated foods that do not compromise on taste or performance.
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.
It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), a vital enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage of creating a first-in-class series of molecules aimed at reactivating this key tumor suppressor. The firm employs proprietary development tools to facilitate rational drug design, aiming to provide therapeutic solutions for various cancer types and select non-oncology conditions.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative immune oncology biopharmaceuticals. Founded in 2016, the company specializes in a bispecific antibody platform designed to engage gamma-delta T cells, which play a crucial role in the immune response against cancer. Lava Therapeutics aims to create next-generation bispecific antibodies that not only activate and recruit the immune system but also enhance its ability to identify and eliminate tumor cells. The company's approach seeks to provide effective, safe, and cost-efficient treatments for both hematological and solid cancers, empowering healthcare professionals to better harness the body's immune capabilities in the fight against cancer.
E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.
Chromologics ApS is a Danish biotechnology company based in Søborg, founded in 2017 as a spin-out from the Technical University of Denmark. The company specializes in the development of bio-based solutions for natural food colorants, with a focus on innovative products that can replace existing natural colorants like carmine and betanin. Chromologics has created a fungal biotechnology platform to produce its flagship product, ChromoRed, which represents a new generation of natural red food colorants. Through its advancements, Chromologics aims to provide sustainable alternatives in the food industry.
ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.
Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders associated with neuronal imbalance. The company's lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently undergoing Phase IIa clinical trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy, and a program for KCNT1 GOF epilepsy. The company engages in collaborations and licensing agreements with various partners, including RogCon Inc., Purdue Neuroscience Company, and Ionis Pharmaceuticals. Founded in 2015, Praxis Precision Medicines is headquartered in Cambridge, Massachusetts.
Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.
Preventice Solutions, Inc. is a provider of healthcare solutions specializing in mobile health technologies and services. Founded in 2007 and based in Eagan, Minnesota, the company offers a range of platforms, including the PatientCare Portal for real-time patient data management, the PatientView Portal for healthcare organizations, and the PatientFlow Portal for monitoring centers. Preventice is known for its advanced wearable monitoring devices, such as the BodyGuardian Heart, which enhances patient mobility and compliance, and the BodyGuardian Verité, a dual-modality cardiac sensor. These technologies aim to facilitate the monitoring and management of patients with cardiac issues, improving health outcomes while potentially reducing the cost of care. The company was formed through the merger of Preventice Services and Preventice Technologies in 2014, and it operates additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.
Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.
Bolt Biotherapeutics is a biotechnology company focused on developing innovative cancer treatments through its Boltbody platform, which centers on immune-stimulating antibody conjugates (ISAC). This platform combines tumor-targeting antibodies with potent immune stimulants, such as TLR agonists, to transform cold tumors into immunologically active ones and facilitate tumor elimination. One of the company's key developments is BDC-1001, designed as a monotherapy for patients with HER2-expressing solid tumors. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics aims to advance cancer immunotherapy and improve patient outcomes. The company was previously known as Bolt Therapeutics before rebranding in July 2015.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.
Kebotix, Inc. is a company focused on revolutionizing the materials discovery and production process through the integration of artificial intelligence, machine learning, and robotics. Founded in 2017 and headquartered in Cambridge, Massachusetts, Kebotix has developed a platform that significantly reduces the research cycle for discovering new chemicals and materials from years to mere months. This platform combines advanced AI decision-making with robotic automation, facilitating the efficient creation of innovative materials that enhance public health and promote sustainability. In addition to its core offerings, Kebotix provides partners with access to its digital research and development solutions, enabling the advancement of green chemistry and the reduction of hazardous substances in production processes.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
MycoWorks LLC specializes in the research, design, and manufacturing of sustainable leather alternatives derived from natural mycelium. Established in 2013 and based in San Francisco, the company produces a proprietary material called Reishi, which is water-resistant and customizable in texture and features. Reishi is designed to mimic the performance and feel of traditional leather while being animal-free and environmentally friendly. MycoWorks employs a unique platform known as Fine Mycelium to create this innovative biomaterial, which boasts qualities such as strength, durability, and biodegradability. The company aims to provide natural alternatives to conventional materials like plastic foams, textiles, and leather, catering to industries such as aerospace, automotive, apparel, and architectural interiors. Through its carbon-negative production process, MycoWorks offers a rapidly grown solution that aligns with sustainable design principles.
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare endocrine disorders. Founded in 2014 and based in Daly City, California, the company is primarily focused on its lead candidate, tildacerfont, which is being evaluated in Phase II clinical trials for classic congenital adrenal hyperplasia (CAH) in both adults and children. Tildacerfont aims to be the first non-steroidal treatment that enhances disease control while minimizing the reliance on steroids for managing CAH. Additionally, Spruce Biosciences is exploring tildacerfont's potential applications in treating polycystic ovary syndrome in women. The company has also entered a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications. Through its efforts, Spruce Biosciences seeks to significantly improve the quality of life for patients with rare endocrine disorders who have historically been underserved by medical advancements.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for the treatment of acute and chronic liver diseases. The company’s approach centers on the mitogen-activated protein kinase (MAPK) pathway, specifically targeting MAP kinase kinase 4 (MKK4), a crucial regulator of liver regeneration. Research conducted by Professor Lars Zender and his team at the University Hospital Tübingen has demonstrated that small RNA molecules can suppress MKK4 gene expression, thereby restoring the regenerative capacity of hepatocytes even in severely diseased livers. HepaRegeniX is advancing the development of small-molecule MKK4 inhibitors, which have the potential to address liver disorders, including nonalcoholic steatohepatitis, by enhancing liver regeneration.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.
It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Private Equity Round in 2019
WCG is a prominent provider of regulatory and ethical review services for human research, focusing on enhancing the quality and efficiency of clinical studies. The company reviews new research protocols and offers a range of services including clinical and human gene therapy research, laboratory biosafety consulting, and solutions for human research protections. WCG also provides online learning resources, an electronic informed consent solution to streamline clinical processes, oncology review services, and a cloud-based platform for managing research activities. Serving a diverse clientele that includes large pharmaceutical companies, biotechnology firms, and contract research organizations, WCG is committed to accelerating the delivery of new treatments while upholding high standards of human subject protection. Founded in 2012 and headquartered in Princeton, New Jersey, WCG operates multiple locations across the United States and in Tokyo, Japan, and has established a strategic partnership with InformedDNA.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Allievex is a clinical-stage biotechnology company
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.
Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.